Spectrum Pharma (SPPI) Meets with U.S. FDA for FUSILEV; FDA is Requesting More Data, No More Efficacy Studies
Tweet Send to a Friend
Spectrum Pharmaceuticals (NASDAQ: SPPI) today announced that it has met with the FDA regarding it's supplemental New Drug Application (sNDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
